192 related articles for article (PubMed ID: 28370903)
1. Impact of post-transplant minimal residual disease on the clinical outcome of pediatric acute leukemia.
Umeda K; Iwai A; Kawaguchi K; Mikami M; Nodomi S; Saida S; Hiramatsu H; Heike T; Ohmori K; Adachi S
Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28370903
[TBL] [Abstract][Full Text] [Related]
2. Impact of pretransplant minimal residual disease on the post-transplant outcome of pediatric acute lymphoblastic leukemia.
Umeda K; Hiramatsu H; Kawaguchi K; Iwai A; Mikami M; Nodomi S; Saida S; Heike T; Ohomori K; Adachi S
Pediatr Transplant; 2016 Aug; 20(5):692-6. PubMed ID: 27256540
[TBL] [Abstract][Full Text] [Related]
3. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
4. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
5. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
6. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
Czyz A; Nagler A
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
[TBL] [Abstract][Full Text] [Related]
7. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
8. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
[TBL] [Abstract][Full Text] [Related]
9. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
12. [Flow cytometric monitoring of minimal residual diseases in patients with acute leukemia after allogeneic hemapoietic stem cell transplantation].
Gao YQ; Wu T; Wang H; Tong CR; Zhang WJ; Wang JB; Lu Y; Zhao YL; Zhou JR; Sun Y; Zhang YC; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):84-7. PubMed ID: 22730653
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.
Selim A; Alvaro F; Cole CH; Fraser CJ; Mechinaud F; O'Brien TA; Shaw PJ; Tapp H; Teague L; Nivison-Smith I; Moore AS
Pediatr Blood Cancer; 2019 Aug; 66(8):e27812. PubMed ID: 31111633
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
16. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
[TBL] [Abstract][Full Text] [Related]
19. [Significance of Monitoring Minimal Residual Disease by Flow Cytometry in Acute Leukemia Patients Underwent Nonmyeloablative Allo-HSCT].
Liu XX; Liu TQ; Guo M; Sun QY; Qiao JH; Hu KX; Li BX; Yao B; Yu CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):873-879. PubMed ID: 28641652
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
